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ABBREVIATIONS 
BMI, body mass index; CI, confidence interval; DCD, donation after cardiac death; DRI, Donor 
Risk Index; DSA, donor specific area; HCC, hepatocellular carcinoma; HR, hazard ratio; ICU, 
intensive care unit; MELD score, Model for End-Stage Liver Disease score; POT, Probability of 
90-day waitlist Transplant; POD, Probability of 90-day waitlist Death; SBP, spontaneous 
bacterial peritonitis; TI, Transplant Index; UNOS, United Network for Organ Sharing 
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ABSTRACT 
 
 Background: The field of transplantation is shifting outcome priorities from 1-year 
survival to more comprehensive metrics including transplant rate and waitlist mortality.  
Identifying disenfranchised candidates (high waitlist death risk, low transplantation chance) can 
be a focus to improve outcomes.  
 
           Methods: Given waitlist outcomes, (continued waiting, death, and transplantation), we 
aimed to identify factors predicting the likelihood candidates would undergo transplant or death 
by performing multivariate competing risk analyses of 121 198 candidates in the United Network 
for Organ Sharing database. We incorporated these probabilities (likelihood of transplantation 
and waitlist death) into the transplant index (TI) to identify disenfranchised candidates (high 
likelihood of death, low likelihood of transplantation).  
 
           Results: Half of the patients had low incidences of death and transplantation within 90 
days (TI-inactive). The remaining were stratified into 10 groups within a predictive index, the TI. 
Low-TI groups (TI-10, 20, 30) had 90-day transplant rates of 50.8%, 41.6%, and 39.8% 
respectively, and their respective 90-day death rates were 22.8%, 15.1%, and 10.9%. High-TI 
groups (TI 80, 90, >90) had 90-day transplantation rates of 53.7%, 64.3%, and 73.9% 
respectively, and 90-day death rates of 5.9%, 6.5%, and 6.7% respectively. As TI increased, the 
likelihood of transplantation increased and that of death decreased. Low-TI groups represent the 
disenfranchised candidates.  
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           Conclusions: The TI identifies disenfranchised candidates on the adult liver transplant 
waitlist. This is the subgroup that would benefit the most from efforts to increase access to 
transplantation. 
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1. INTRODUCTION The most critical factor limiting access to liver transplantation is the 
limited supply of deceased donor allografts. Increasing organ utilization of the existing donor 
supply becomes the key to increasing rates of transplantation.
1, 2
 Identifying disenfranchised 
(high risk of death on the waitlist, low chance of transplantation) candidates and increasing organ 
utilization for these patients, will have the greatest impact on waitlist outcomes. While there are 
several strategies to increase organ utilization, the most prominent is the use of marginal or 
“extended-criteria donors”, which has been reported to reduce pretransplant mortality by up to 
50%.
3, 4
 “Extended-criteria donor” is a broad and imprecise term that incorporates many different 
types of allografts, including older and steatotic allografts, CDC high risk allografts, Hepatitis B 
positive allografts, Hepatitis C positive allografts, donors with CNS malignancies, and donors 
with hypercoagulable states, among others.
5, 6
 A second prominent strategy to increase access to 
transplantation is the use of living donors.
7
 Finally, more conservative recipient exclusion 
criterion and more aggressive acceptance of donor offers in a general sense may serve to increase 
organ utilization and can be done while preserving posttransplant outcomes.
8, 9
 A model to help 
physicians and candidates understand the likelihood of death vs. transplantation could assist 
identifying disenfranchised candidates (high risk of death on the waitlist, low chance of 
transplantation) that would benefit most from strategies to increase access to transplantation. We 
sought to identify factors predicting the likelihood of waitlist activity (transplantation or death) 
and then to use competing risk and cox regression analyses to stratify candidates based on the 
likelihood of 90-day liver transplantation vs. death. 
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2. METHODS  
 
2.1 Study Population. In our retrospective analysis of United Network for Organ Sharing 
(UNOS) deidentified patient-level data, we reviewed the records of all candidates listed for liver 
transplantation from March 1, 2002, through September 30, 2016 (n = 166 162). We excluded 
the following: candidates younger than 18 years (n = 11 407); candidates listed for a combined 
liver-heart, liver-lung, or liver-intestine transplant (n = 636); candidates with board-approved 
exception points for hepatocellular carcinoma (HCC) or other reasons (n = 29 806); and 
candidates who underwent a living donor liver transplant (n = 3115). A separate analysis was 
conducted solely with candidates with board-approved exception points (n = 29 806).  All 
candidates were followed until death or the date of last known follow-up. We included 121 198 
candidates in our final study group. This study was conducted in compliance with local 
institutional review board requirements. The UNOS data was already deidentified when obtained 
and any potential identifiers were further codified for analysis. 
 
2.2 Statistical Analysis. Variables with low levels of completion in the UNOS database were 
excluded from the analyses. Continuous variables were reported as the mean ± standard 
deviation and compared using the Student t test. Categorical variables were summarized as 
frequencies and percentages, and compared using the Chi-square test. Time to Transplant was 
analyzed using the competing risk method with death as a competing risk for transplant.
10
 Time 
to death was analyzed using the Cox proportional regression survival analysis. All variables with 
p values < 0.05 in the univariate analysis were included in the multivariate analyses. All reported 
P values were 2-sided.  
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2.3 Transplant Index (TI). Separate regression equations for the probability of 90-day waitlist 
transplantation (POT) and probability of 90-day waitlist death (POD) were generated utilizing 
the competing risk method (Figure1a). Waitlist activity was calculated by taking the sum of POT 
and POD (Figure 1b). The 50% of candidates with the lowest levels of waitlist activity, ie, low 
incidences of both death and transplantation, were identified as TI-inactive. Using the regression 
equations for POT and POD, the Transplant-Index was calculated as their mathematical 
difference (Figure 1b). For the remaining 50% of candidates (not TI-inactive), we individually 
calculated the TI and stratified them into 10 roughly equal groups (TI-10, 20, 30, 40, 50, 60, 70, 
80, 90, >90), thus identifying patients with disproportionate likelihoods of transplant vs. death.  
 
2.4 Predictors. Recipient and donor risk factors included in the multivariable analysis are listed 
in Tables 1 and 2. All available potential predictors were recorded, for each candidate, at the 
time of listing.  
 
3. RESULTS  
 
3.1 Study Population. After exclusions, our final study group included 121 198 candidates. The 
mean age of the candidates was 51.9 ± 10.4 years. The average MELD score at transplant was 
22.3 ± 11.1. Demographic and clinical characteristics, summarized by TI category, are in Table 
3.  
 
3.2 Waitlist Activity. Similar to the ability of the MELD score to predict waitlist mortality, we 
used 90 days as the cutoff for waitlist activity (death and transplantation). As previously 
mentioned, waitlist activity was calculated as the mathematical sum of POT and POD. 
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Candidates with waitlist activity ≤ 0.299 (lower 50% of candidates) were considered TI-inactive 
(n=61 274 patients), and had extremely low rates of both transplantation and death (6.3 and 
2.5%, respectively). Candidates with waitlist activity >0.299 had their TI calculated. Rates of 90-
day death and transplantation by TI category are listed in Table 4.  
 
3.3 Transplant Index. The components of our Transplant Index are highlighted in Figure 1. The 
TI includes the following factors: age, MELD, etiology of liver disease (hepatitis C, alcohol, 
autoimmune, NASH), need for preoperative life support (vasopressors and/or mechanical 
ventilation or other circulatory support), transjugular intrahepatic portosystemic shunt (TIPS), 
retransplant, UNOS region of listing, diabetes mellitus, ABO blood type, hemodialysis, and 
spontaneous bacterial peritonitis. The probability of transplantation was higher than that of death 
across all groups. We considered candidates in TI-10, 20 to have disproportionately higher death 
rates compared to higher TI groups (Figure 2). Similarly, candidates in TI- 10, 20 and TI-80, 90 
groups had higher MELD scores than the rest of the candidates, with the average MELD score 
for the Low-TI groups (TI-10, 20) being 31.1, while that of the High-TI groups was 29 (Figure 
3). When analyzing the exception point cohort, 90-day mortality was inordinately low (1.4%) 
and so competing risk modeling did not result in a reliable predictive index for this subject 
population.   
 
3.4 Model Discrimination. Our regression equation to predict 90-day transplantation had a C 
statistic of 0.82. Our regression equation to predict 90-day mortality had a C statistic of 0.77. For 
reference, the MELD score has previously been validated to predict 90-day waitlist mortality 
with a C statistic of 0.73.
11
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3.5 Waitlist and Posttransplant survival. Low-TI candidates that underwent transplantation 
achieved slightly lower 1-yr survival versus their high-TI counterparts (82% vs 88%, p<0.01) 
(Figure 4a).  Waitlist 1-yr survival was exceptionally low for low-TI candidates (39%).  The 
relative survival benefit was a 49% increase in 1-yr survival if a low-TI candidate was able to be 
transplanted (Figure 4b). 
 
4. DISCUSSION As demonstrated by this study, there is significant heterogeneity regarding the 
relative likelihoods of transplantation and death among transplant candidates on the waitlist 
outside of that predicted by the MELD score. Applying the TI, we identified a significant portion 
of waitlisted patients with disproportionate risks of 90-day mortality relative to the likelihood of 
transplantation. It is these patients whom we believe are disenfranchised with regard to access to 
transplantation.  
 
The TI identifies patients that would receive the most benefit from efforts to increase access to 
transplantation. Those low-Ti candidates that underwent transplantation had a substantial 
survival benefit and fared very poorly on the waitlist. Although it identifies disenfranchised 
patients (highest likelihood of death and lowest likelihood of transplantation), it does not identify 
which patients are likely to have the best outcomes after transplantation. Identifying these 
candidates often requires nuanced clinical judgement that is not easily captured by a 
mathematical index. For example, the use of extended-criteria deceased donors has been shown 
to be independently associated with inferior outcomes and increased costs.
12
 Older donors have 
been associated with decreased patient and graft survival rates.
13
 Prolonged cold ischemia time 
has been associated with increased hospital stays, biliary strictures, and decreased graft survival 
rates.
14-16
 Steatotic allografts have been linked to increased rates of primary nonfunction, as well 
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as to decreased graft and patient survival rates.
16-18
 Several studies have linked DCD (donation 
after cardiac death) donors with increased morbidity rates associated with biliary strictures and 
with decreased graft and patient survival rates.
19, 20
 The TI does not instruct clinicians which 
candidates are likely to do well with extended criteria donors. However, it does instruct 
clinicians as to which group of candidates would derive the most benefit in access to 
transplantation from extended-criteria donors.  
 
Additionally, many of the low-TI candidates have characteristics unfavorable for transplantation 
(older age, life support, comorbid diagnoses) and there may be a portion of these candidates that 
are truly unfit for transplantation.  However, although low- and high-TI candidates had markedly 
disparate rates of transplantation, we found that they both had acceptable posttransplant 
survival.  These data show that although some of the low-TI candidates may not be eligible for 
transplantation, eg, too sick, there are some that can achieve acceptable survival and so should be 
identified and pursued.  
 
Identifying these disenfranchised individuals, perhaps through a center watch-list of low-TI 
candidates, could be a clinical role for the TI in waitlist management and organ allocation. The 
candidates on such a watch-list may be given priority consideration of an extended-criteria donor 
organ offer.  Center-level decision making undoubtedly plays a large role in the disparate rates of 
transplantation across the TI groups, as evidenced by the significance of listing region in the 
multivariate analysis.  Given that both low- and high-TI candidates have relatively high MELD 
scores, the current MELD-based allocation policy would favor transplantation of them both in 
the absence of confounding factors. Although all relevant clinical variables are not captured in 
the OPTN data, the many factors in our analysis reflect some of the decision making involved in 
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deciding which high-risk candidates to transplant. Indeed, our posttransplant survival analysis 
shows that low-TI candidates that do get transplanted have greater than 80% 1-year 
posttransplant survival.  Given that the calculated 1-year waitlist mortality for low-TI candidates 
is more than 50%, we believe identifying which of the low-TI candidates are truly transplantable 
is an important job for the clinician and these data can help guide that process.   
 
The use of competing risk analyses allowed the generation of accurate regression equations with 
a distinct benefit over traditional Kaplan-Meier survival modeling. Considering all the potential 
waitlist outcomes is necessary in real-life waitlist management when trying to identify 
disenfranchised candidates (high likelihood of death, low likelihood of transplantation). Indeed, 
we discovered that the 50% of the waitlist with the lowest levels of 90-day activity (TI inactive, 
n=61 274 patients) had extremely low rates of both transplantation and death (6.3 and 2.5%, 
respectively). Candidates in the TI-inactive group had significantly lower MELD scores, higher 
serum albumin, and higher rates of HCV infection than the other TI categories. The 
disenfranchised candidates in the TI 10, 20 groups (high likelihood of death, low likelihood of 
transplantation) were older with high incidences of DM, HD, life support, and Blood type O. 
Alternatively, candidates in the TI>90 group (high likelihood of transplantation, low likelihood 
of death), were younger with lower incidences of HCV infection, DM, and HD.  
 
Using competing risk analysis, the index can accurately identify disenfranchised candidates (high 
likelihood of death, low likelihood of transplantation). These candidates would benefit the most 
from efforts to increase access to transplantation and have the greatest impact on waitlist 
outcomes.  In conclusion, the TI is a new mathematical index incorporating the important 
outcomes on the waiting list: inactivity, death, and transplantation that can be used to identify 
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candidates on the waitlist that have a high risk of dying and a low probability of undergoing 
transplantation. These disenfranchised candidates are the ones that would benefit the most from 
an increased access to transplantation and after identifying low-TI candidates, deciding which 
are truly transplantable will become an important task. 
 
5. LIMITATIONS Since the passage of the National Organ Transplant Act of 1984, data entry 
has been mandatory for all U.S. transplant centers. Nevertheless, all patient registries often suffer 
from variability in data entry.  Certain granular aspects of clinical variable cannot be gleaned 
from these data, including etiology of renal disease requiring hemodialysis. 
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LEGENDS 
 
Figure 1a. Regression equations for calculating a candidate’s probability of liver transplantation 
(POT) and death (POD) within 90 days becoming active on the waitlist. 
 
Figure 1b. Equations used to calculate the Waitlist Activity and the Transplant Index (TI) 
MELD, Model for End Stage Liver Disease; BMI, Body Mass Index; diag etoh, diagnosis 
alcoholic liver disease; diag nash, nonalcoholic steatohepatitis; diag auto, diagnosis 
autoimmune hepatitis; diag hepc, diagnosis hepatitis C; lifesup, life support; dm, diabetes 
mellitus; tips, transjugular intrahepatic portosystemic shunt; retx, retransplant; sbp, 
spontaneous bacterial peritonitis; abo, ABO blood group; hd, hemodialysis 
 
Figure 2. 90-Day Transplant Rates and 90-Day Death Rates among various Transplant Index 
(TI) categories 
 
Figure 3. MELD Scores of various Transplant Index (TI) Categories 
 
Figure 4. (a) Survival after a Liver Transplant   (b) Survival Benefit in Low TI Candidates 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Table 1. Potential predictors for 90-day waitlist mortality, multivariate analysis 
 
C index= 82.3 %  
  HR 95% CI P 
Initial MELD lab Score 1.081 1.079 1.083 <0.0001 
Initial age 0.997 0.996 0.998 <0.0001 
BMI 1.003 1.001 1.005 0.0029 
Diag EtOH     
    No 1.000    
    Yes 0.969 0.944 0.995 0.021 
Diag autoimmune     
    No 1.000    
    Yes 0.896 0.841 0.954 0.0006 
Diag HCV     
    No 1.000    
    Yes 0.970 0.945 0.995 0.019 
Life Support     
    No 1.000    
    Yes 0.697 0.650 0.748 <0.0001 
DM     
    No 1.000    
    Yes 0.974 0.949 0.999 0.038 
TIPS     
    No 1.000    
    Yes 0.955 0.920 0.991 0.015 
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Retransplant     
    No 1.000    
    Yes 1.057 1.007 1.110 0.025 
Region     
    4-7-8 1.000    
    1 0.693 0.653 0.735 <0.0001 
    2 0.949 0.914 0.985 0.006 
    3 2.055 1.986 2.128 <0.0001 
    5 0.753 0.728 0.779 <0.0001 
    6 1.163 1.087 1.244 <0.0001 
    9 0.685 0.651 0.721 <0.0001 
    10 1.665 1.598 1.734 <0.0001 
    11 1.514 1.454 1.576 <0.0001 
SBP     
    No 1.000    
    Yes 1.185 1.136 1.236 <0.0001 
ABO blood type     
    A 1.000    
    AB 2.107 1.998 2.223 <0.0001 
    B 1.251 1.210 1.294 <0.0001 
    O 0.959 0.936 0.982 0.0005 
HD     
    No 1.000    
    Yes 0.781 0.752 0.810 <0.0001 
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Table 2. Potential predictors for 90-day waitlist transplant, multivariate analysis 
 
C index= 77.3%  
  HR 95% CI P 
Initial MELD lab Score 1.101 1.099 1.104 <0.0001 
Initial age 1.024 1.022 1.026 <0.0001 
Diag EtOH     
    No 1.000    
    Yes 0.927 0.892 0.963 0.0001 
Diag NASH     
    No 1.000    
    Yes 0.874 0.823 0.927 <0.0001 
Diag HCV     
    No 1.000    
    Yes 1.106 1.067 1.146 <0.0001 
Life support     
    No 1.000    
    Yes 2.534 2.371 2.708 <0.0001 
DM     
    No 1.000    
    Yes 1.097 1.061 1.134 <0.0001 
TIPS     
    No 1.000    
    Yes 0.871 0.825 0.919 <0.0001 
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Retransplant     
    No 1.000    
    Yes 1.028 0.968 1.092 0.371 
Region     
    4-7-8 1.000    
    1 1.177 1.099 1.260 <0.0001 
    2 1.173 1.119 1.229 <0.0001 
    3 1.042 0.981 1.106 0.181 
    5 1.024 0.982 1.068 0.270 
    6 0.785 0.702 0.877 <0.0001 
    9 1.429 1.357 1.504 <0.0001 
    10 1.174 1.098 1.256 <0.0001 
    11 1.280 1.205 1.359 <0.0001 
SBP     
    No 1.000    
    Yes 1.195 1.128 1.265 <0.0001 
ABO blood type     
    A 1.000    
    AB 0.846 0.765 0.935 0.001 
    B 0.906 0.862 0.952 0.0001 
    O 1.000 0.970 1.032 0.9893 
HD     
    No 1.000    
    Yes 1.470 1.413 1.530 <0.0001 
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Table 3. Demographic and clinical characteristics of 121,198 waitlisted candidates 
 
     
TranspIant Index 
(TI) Category     
 
            
 
 Inacti 
10 20 30 40 50 60 70 80 90 >90 
 
 
ve 
 
           
 
            
 
n 61,27 5,99 5,99 5,99 5,99 5,99 5,99 5,99 5,99 5,99 5,99 
 
(121,198) 4 2 3 2 3 2 3 2 3 2 2 
 
             
 
53.9 
55* 55.6* 
55.6* 54.4* 
53.2* 52.3* 51.5* 
50.3* 49.1* 
45.6* 
 
Age (yr) ±11. ±10. ±10. ±10. ±10. ±12. 
 
±9.8 ±9.7 ±9.5 ±11.1 ±11.8 
 
 
1 3 1 3 9 7 
 
      
 
             
 
15.1 
36.1 
30.1* 27.2* 25.1* 23.8* 23.8* 24.8* 26.7* 28.8* 31.5* 
 
MELD-Na * 
 
±10 ±7.6 ±6.8 ±7.2 ±7.7 ±7.7 ±7.7 ±7.5 ±7.1 ±6.3 
 
 
±8 
 
           
 
             
DM (%) 25.7 
29.4 
32* 27.9* 25.5 25.5 24.6 23.4* 20.7* 18.3* 15.3* 
 
* 
 
           
 
            
 
HCV (%) 30.7 
21.6 
27.1* 27.6* 26.4* 25.5* 22.9* 22.1* 20.4* 19.1* 15* 
 
* 
 
           
 
            
 
ABO - O (%) 49.2 
52.8 
50.8* 49.9 47.3* 45* 42.1* 43.1* 40* 39* 31.9* 
 
* 
 
           
 
            
 
ABO – A (%) 38.4 37.4 38.7 38.9 39.6 37.6 38.3 35.8* 35.6* 33* 27.1* 
 
            
 
ABO – B 
10.7 8.9* 9.4* 10.2 11.4 13.7* 14.3* 14.7* 16.8* 18* 20.7* 
 
(%) 
 
           
 
             
ABO – AB 
1.8 1* 1.2* 1* 1.7 3.7* 5.3* 6.4* 7.6* 10* 20.3* 
 
(%) 
 
           
 
            
 
Restranspla 
2 9.2* 5.5* 4.6* 3.7* 4.1* 4.3* 5* 5.8* 7.7* 9.8* 
 
nt (%) 
 
           
 
             
SBP (%) 3.5 
11.4 
10.6* 9.9* 9.1* 8.3* 7.9* 9.1* 10* 10.1* 10.3* 
 
* 
 
           
 
            
 
HD (%) 6.8 
71.9 
55.8* 27* 14.6* 10.6* 9.6* 9.3* 8.6* 7.7* 4.7* 
 
* 
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Life Support 
0.9 
66.2 
14.6* 5.6* 2.7* 2.1* 1.7* 1.4* 1.4* 1.5* 0.7* 
 
(%) * 
 
          
 
             
Albumin (g/ 3.14 
3.02 
2.92* 2.84* 2.84* 2.86* 2.89* 2.85* 2.83* 2.83* 2.84* 
 
* 
 
dL) ±0.6 ±0.8 ±0.7 ±0.7 ±0.7 ±0.7 ±0.7 ±0.7 ±0.7 ±0.8 
 
±0.8 
 
           
 
             
 
* p<0.05 compared to TI inactive 
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Table 4. 90-Day Transplant Rate and 90-Day Death Rate of various Transplant Index (TI) 
Categories 
 
 TI Category TI Values Transplant 
Rate (%) 
Death Rate (%) 
TI-inactive * 6.3 2.5 
TI 10 ≤ 0.031 50.8 22.8 
TI 20 > 0.031, ≤ 0.131 41.6 15.1 
TI 30 > 0.131, ≤ 0.184 39.8 10.9 
TI 40 > 0.184, ≤0.220 37.7 8.6 
TI 50 > 0.220, ≤ 0.250 37.3 6 
TI 60 > 0.250, ≤ 0.283 39 6 
TI 70 > 0.282, ≤ 0.322 44.6 6.2 
TI 80 > 0.322, ≤ 0.375 53.7 5.9 
TI 90 > 0.375, ≤ 0.462 64.3 6.5 
TI over 90 > 0.462 73.9 6.7 
 
* TI-inactive category has waitlist activity of < 0.299. 
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